Compare CRBU & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRBU | BNR |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.9M | 233.6M |
| IPO Year | 2021 | 2020 |
| Metric | CRBU | BNR |
|---|---|---|
| Price | $1.64 | $20.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.33 | N/A |
| AVG Volume (30 Days) | ★ 928.4K | 64.5K |
| Earning Date | 11-12-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $9,295,000.00 | ★ $75,749,382.00 |
| Revenue This Year | N/A | $136.32 |
| Revenue Next Year | $3.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5.56 |
| 52 Week Low | $0.66 | $2.18 |
| 52 Week High | $3.54 | $24.18 |
| Indicator | CRBU | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 38.12 | 57.00 |
| Support Level | $1.63 | $19.49 |
| Resistance Level | $1.73 | $21.57 |
| Average True Range (ATR) | 0.09 | 1.89 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 8.62 | 59.13 |
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.